Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lenz

Showing results (121-130 of 294) with videos related to

Pageof 30
Sort By:
Angewandte Chemie (International Ed. in English)|November 2, 2021
Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs)Andreas Faust, Nicole Bäumer, Alina Schlütermann, et al.
Frontiers in Cell and Developmental Biology|August 22, 2025
Prognostic marker Musashi-2 modulates DNA damage response and radioresistance in diffuse large B-cell lymphomaTimo Habig, Lasse Reichstein, Kathrin A Brücksken, et al.
Blood Advances|September 24, 2021
Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AMLLinus Angenendt, Marius Wöste, Jan-Henrik Mikesch, et al.
Annals of Hematology|September 3, 2021
The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysisRamona Wullenkord, Philipp Berning, Anna-Lena Niemann, et al.
British Journal of Haematology|December 7, 2018
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trialBirte Friedrichs, Maike Nickelsen, Marita Ziepert, et al.
British Journal of Haematology|June 9, 2020
Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemiaMatthias Floeth, Sandra Elges, Joachim Gerss, et al.
Cancers|May 16, 2023
Radiomics of Tumor Heterogeneity in <sup>18</sup>F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung CancerDavid Ventura, Philipp Schindler, Max Masthoff, et al.
Ejhaem|February 26, 2024
Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysisInna Shaforostova, Simon Call, Georg Evers, et al.
Cancers|December 10, 2021
Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant DiseaseMirjam Gerwing, Tobias Krähling, Christoph Schliemann, et al.
Plos One|February 22, 2020
Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcomaCaroline Brand, Burkhard Greve, Tobias Bölling, et al.
Pageof 30

Showing results (121-130 of 294) with videos related to

Sort By:
Pageof 30
Angewandte Chemie (International Ed. in English)|November 2, 2021
Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs)Andreas Faust, Nicole Bäumer, Alina Schlütermann, et al.
Frontiers in Cell and Developmental Biology|August 22, 2025
Prognostic marker Musashi-2 modulates DNA damage response and radioresistance in diffuse large B-cell lymphomaTimo Habig, Lasse Reichstein, Kathrin A Brücksken, et al.
Blood Advances|September 24, 2021
Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AMLLinus Angenendt, Marius Wöste, Jan-Henrik Mikesch, et al.
Annals of Hematology|September 3, 2021
The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysisRamona Wullenkord, Philipp Berning, Anna-Lena Niemann, et al.
British Journal of Haematology|December 7, 2018
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trialBirte Friedrichs, Maike Nickelsen, Marita Ziepert, et al.
British Journal of Haematology|June 9, 2020
Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemiaMatthias Floeth, Sandra Elges, Joachim Gerss, et al.
Cancers|May 16, 2023
Radiomics of Tumor Heterogeneity in <sup>18</sup>F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung CancerDavid Ventura, Philipp Schindler, Max Masthoff, et al.
Ejhaem|February 26, 2024
Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysisInna Shaforostova, Simon Call, Georg Evers, et al.
Cancers|December 10, 2021
Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant DiseaseMirjam Gerwing, Tobias Krähling, Christoph Schliemann, et al.
Plos One|February 22, 2020
Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcomaCaroline Brand, Burkhard Greve, Tobias Bölling, et al.
Pageof 30